Kneu Health raises £4.18m led by Oxford Science Enterprises and Cedars Sinai
At a glance
This article covers a seed round on 9 October 2025 for Kneu Health, a precision neurology platform for Parkinson's and dementia, founded by Caroline Cake. The round raised £4.18m and was co-led by Oxford Science Enterprises and Cedars-Sinai.
What does Kneu Health do?
Kneu Health is a neurology platform that uses smartphone interactions and AI to assess speech, movement and cognition. It generates predictive biomarkers and clinical measurements for remote monitoring and to inform treatment decisions.
Why is Kneu Health useful?
Problem
Hospitals face long waits and neurologist shortages that delay diagnosis and treatment for Parkinson's and dementia patients. Care is often reactive, missing gradual decline and preventing timely support for patients and families.
Solution
Kneu Health explains that it uses smartphone-based monitoring and clinically trained AI to analyse speech, movement and cognition. This generates predictive biomarkers clinicians can use to monitor patients continuously, speed up treatment access and guide interventions.
How much did Kneu Health raise?
Kneu Health raised £4.18m ($5.6m) in an oversubscribed seed round, co-led by Oxford Science Enterprises and Cedars-Sinai. This makes it the 11th largest funding round in October 2025 (27 recorded). The deal is also 242nd among UK investments this year (499 recorded) in the Startupmag database, as of 9 October 2025.
For details on how Startupmag compiles its rankings, view our Methodology.
Who invested in Kneu Health?
The key investors in the round were:
- Oxford Science Enterprises: A UK-based investment company that invests in early-stage deep-tech and life-science companies emerging from university research.
- Cedars-Sinai: The venture arm of the US health system that invests in clinical and health-technology innovations and supports partnerships within healthcare ecosystems.
- Social Impact Enterprises: An investor focused on social-impact and mission-driven ventures that support health and social outcomes.
- JIMCO: An institutional investor active across international markets with investments spanning multiple sectors, including healthcare.
- G.K. Goh Ventures: A Singapore-based investment firm that backs early-stage technology and healthcare startups across Asia and beyond.
- SXSW London: The UK arm of the SXSW programmes that supports cultural and technology initiatives and participates in programme-based investments and partnerships.
In the funding announcement, Joel Schoppig from Oxford Science Enterprises said:
Neurology has had plenty of algorithms. What it has lacked is longitudinal signal that clinicians can trust and act on inside real workflows.
The investor added that Kneu converts everyday phone interactions into a clinically governed measurement layer that scales without new hardware or staffing and is building a reference dataset and operating platform for Parkinson's and dementia to improve standards of care and economic viability for hospitals and payers.
In the funding announcement, Nirdesh Gupta from Cedars-Sinai Technology Ventures said:
The strength of Kneu's approach is how rigorous science is carried through into day-to-day practice. By giving neurologists longitudinal signal between visits, the platform reduces avoidable appointments and sharpens focus on the cases that matter most.
The investor added that this clinically governed infrastructure is the reason Cedars-Sinai chose to back Kneu and integrate it into their ecosystem.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Who founded Kneu Health?
Caroline Cake is the founder of Kneu Health.
In the funding announcement, Caroline Cake explained:
We've spent the last two years proving that remote monitoring can transform neurological care. Clinicians are getting clearer insight without added workload, patients no longer face months of uncertainty between visits, and gain confidence that changes will be recognized rather than missed,
The company continued that the funding will allow it to bring that model to the U.S. at the right moment, when health systems are ready to move beyond band-aid solutions and embrace continuous neurological care as core infrastructure, accessible to anyone with a smartphone.
Where is Kneu Health based?
Kneu Health is based in London, UK.
What sector is Kneu Health in?
Kneu Health operates in the healthtech sector. It develops digital tools and services to improve healthcare, diagnosis and patient monitoring. This means using technology to help doctors and patients manage illness more effectively.
Key trends and challenges in Neurology:
Rising disease burden
Dementia cases are projected to triple by 2050, and Parkinson's is the fastest-growing neurological disease.
Shift to continuous digital monitoring
Smartphone sensors and digital biomarkers enable continuous home monitoring, with some smartphone measures receiving regulatory approval.
Workforce shortages and delayed care
Patients often wait many months between specialist visits, worsening care and delaying needed treatment changes.
For a deeper look at innovation in this space, see the healthtech startups in the UK.
They've invested in Kneu Health
Get to know these healthtech investors
Click here for a full list of 7,233+ startup investors in the UK